Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

By D. Mauri, N. Pavlidis, John P. A. Ioannidis. Journal of the National Cancer Institute, 2005

1,106 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/53fbf701cfb911e69e09a1070db7359f7a382d65

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Lisa A. Carey

Citations in the corpus

• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, background): “A response to neoadjuvant therapy can result in downstaging of a tumor and therefore can improve tumor resectability, enhance cosmesis, and reduce postoperative complications.(71) Evidence for the reduction in the extent of local therapy associated with neoadjuvant chemotherapy comes from several la”
• Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis (2020, neutral): “Studies have demonstrated no difference in survival between adjuvant or neoadjuvant setting (1, 2).”